Tags » GlaxoSmithKline

Why GSK's Experimental HIV Drug Could Be a Safer Bet—And a Headache for Gilead

An experimental therapy from GlaxoSmithKline could be just as effective as existing therapies for HIV/AIDS patients without the corresponding risk of toxic side effects, raising the possibility of a challenge to incumbent companies in the space like Gilead . 273 more words


Innovative Approach To AIDS Treatment Revealed By Glaxo

Phase-three trial results of ViiV Healthcare’s new HIV drug in adual-drug regimen proved to be successful. The latest progress of ViiV Healthcare—a unit of GlaxoSmithKline PLC—can boost the company’s chances of hitting their bets on their ability to modify the three-drug combinations that try to treat AIDS. 313 more words

Exo Capital Markets

GlaxoSmithKline tops access to medicine list for fifth time

#GlaxoSmithKline  GlaxoSmithKline tops access to medicine list for fifth time  British firm GlaxoSmithKline has come top of the Access to Medicine index, which ranks the 20 leading pharmaceutical companies operating in developing countries every two years. 39 more words

The 4 Best Brexit-Proof Foreign Stocks to Buy for 2017

After the U.K. voted in June to leave the EU, global stocks went into a tailspin—and almost immediately shrugged it off. Even blue-chip U.K. stocks traded at a premium (see chart below), as investors flocked to Britain-based multinationals, which got an added foreign-exchange boost thanks to the weakened pound. 395 more words


GSK kicks off final phase of testing anaemia drug

GlaxoSmithKline has started a phase III development programme investigating daprodustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), as a treatment for anaemia associated with chronic kidney disease (CKD). 291 more words


GSK study of Nucala for rare EGPA disease goes well, one non-related death

GlaxoSmithKline has announced today that both all endpoints were met in a pivotal phase III study of mepolizumab for rare disease Eosinophilic Granulomatosis with Polyangiitis (EGPA), approved as Nucala as an add-on treatment for some types of asthma in adult patients, and teenage patients in the U.S. 299 more words


GSK files for chronic lung disease drug to FDA

GlaxoSmithKline has submitted with the US Food and Drug Administration (FDA) for its drug against lung disease – chronic obstructive pulmonary disease (COPD).

The announcement by GlaxoSmithKline and Innovivatoday, of the filing for the once-daily, closed triple combination therapy fluticasone furoate/ umeclidinium/ vilanterol (FF/UMEC/VI 100/62.5/25 mcg) for patients with chronic obstructive pulmonary disease (COPD), follows the announcement earlier this year of plans to bring forward the timing of the US filing from the first half of 2018. 289 more words